A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT ID: NCT06072183
Last Updated: 2025-08-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
1571 participants
INTERVENTIONAL
2023-11-08
2027-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Ritlecitinib has been tested in earlier clinical studies and has a favorable safety profile. At present there are no approved medications taken by mouth to treat nonsegmental vitiligo.
This study is seeking participants who:
* Are 18 years of age or older.
* are confirmed to have nonsegmental vitiligo for at least 3 months.
* Are willing to stop all other treatments that they may be taking for vitiligo.
In this study participants will be chosen by chance, like drawing names out of a hat to receive 1 of 3 treatments:
•Part I where two different amounts of ritlecitinib (50 mg and 100 mg) are taken once daily. It will be compared to placebo. Placebo is a dummy capsule. It doesn't have any medicine used in the study.
Participants receiving placebo who have not responded to treatment after 52 weeks will be given 100 milligrams or 50 milligrams of ritlecitinib for the remaining 52 weeks of the study.
• In Part II, participants will only receive 100 milligrams of ritlecitinib. About 1000 participants will take part in Part I and around 450 in Part II globally. The study will compare the experiences of people receiving ritlecitinib to those of the people who do not. This will help see if ritlecitinib is safe and effective.
People in Part I will be in this study for about 26 months and people in Part II will be in this study for about 14 months. During the study, participants in part I will need to visit the study site at least 17 times. In part II, participants will visit at least 11 times.
Participants will undergo various tests and procedures such as:
* vitiligo rating,
* physical examinations,
* hearing tests,
* blood tests,
* x-ray,
* ECG,
* photographs of areas with vitiligo. Participants will be asked to complete questionnaires about their vitiligo.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326
Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
NCT04530344
Secukinumab in Active Non-segmental Vitiligo
NCT05676333
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
NCT06548360
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo
NCT04818346
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1- Ritlecitinib 100 milligrams (mg)
Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
Ritlecitinib
100mg Capsule
Arm 2- Ritlecitinib 50mg
Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
Ritlecitinib
50mg Capsule
Arm 3- Placebo
Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.
Placebo
Matching capsule
Arm 4- Ritlecitinib 100mg
Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks.
Ritlecitinib
100mg Capsule
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ritlecitinib
100mg Capsule
Ritlecitinib
50mg Capsule
Placebo
Matching capsule
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
• Meeting reproductive criteria for female participants.
Disease Characteristics:
2. Eligible participants must have at both Screening and BL:
* A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and
* BSA involvement 4% to 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet and
* BSA ≥0.5% involvement on the face. Face is defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. Face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
* F-VASI ≥0.5 and T-VASI ≥3; and
* Either active or stable nonsegmental vitiligo at Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease.
Active vitiligo is defined as:
Participants will be classified as having active vitiligo based on the presence of at least one active lesion at BL defined as one of the following:
* New/extending lesions(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record);
* Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters;
* Trichrome lesion(s); Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin;
* Koebner phenomenon/phenomena (excluding Type 1 \[history based on isomorphic reaction\]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.
Stable vitiligo is defined as:
• Participants will be classified as having stable vitiligo based on an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) will be classified as having stable disease.
Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.
* If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
* Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.
* Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, malignancy-induced hypopigmentation \[melanoma and mycosis fungoides\], post-inflammatory hypopigmentation, pityriasis alba \[minor manifestation of atopic dermatitis\], senile leukoderma \[age-related depigmentation\], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
* Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or BL Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
* Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions or leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
* Have a superficial skin infection within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
3. General Infection History:
* Have a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged clinically significant by the investigator within 6 months prior to Day 1.
* Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.
* Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis.
4. Specific Viral Infection History:
* History (single episode) of disseminated HZ or disseminated herpes simplex or recurrent (more than one episode of) localized, dermatomal HZ.
* Infected with HBV or HCV: all participants will undergo screening for HBV and HBC for eligibility.
* Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.
* Have a known immunodeficiency disorder (including positive serology for HIV at screening) or a first-degree relative with a hereditary immunodeficiency.
5. Other Medical Conditions:
* Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements.
* History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/hypersensitivity to any component (including excipients) of the study intervention.
* Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered current, fluctuating, or progressive.
* Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
* Abnormal findings on the Screening chest imaging (eg, chest x-ray). Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation.
* Long QT Syndrome, a family history of Long QT Syndrome, or a history of TdP.
* Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
* Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.
Prior/Concomitant Therapy:
6. Have received any of the prohibited treatment regimens specified.
Prior/Concurrent Clinical Study Experience:
7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 \[Baseline\] or within 5 half-lives, whichever is longer.
Diagnostic Assessments:
Any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:
8. Renal impairment
9. Hepatic dysfunction
10. Other laboratory abnormalities
11. Standard 12-lead ECG that demonstrates clinically relevant abnormalities
Exclusion Criteria
1. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
• Any psychiatric condition including recent or active suicidal ideation or behavior that meets defined criteria.
2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:
12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Center for Dermatology and Plastic Surgery/CCT Research
Scottsdale, Arizona, United States
Dermatology Trial Associates
Bryant, Arkansas, United States
First OC Dermatology Research Inc
Fountain Valley, California, United States
Seaside Audiology Vertigo & Ear Specialists
Huntington Beach, California, United States
Wallace Medical Group, Inc
Los Angeles, California, United States
Kaiser Permanente
Oakland, California, United States
Cura Clinical Research - Oxnard
Oxnard, California, United States
Mission Dermatology Center
Rancho Santa Margarita, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Integrative Skin Science and Research
Sacramento, California, United States
University of California San Diego - La Jolla
San Diego, California, United States
Wolverine Clinical Trials
Santa Ana, California, United States
Encore Medical Research of Boynton Beach
Boynton Beach, Florida, United States
FXM Clinical Research - Fort Lauderdale
Fort Lauderdale, Florida, United States
Direct Helpers Research Center
Hialeah, Florida, United States
Harmony Medical Research Institute
Hialeah, Florida, United States
Clever Medical Research
Miami, Florida, United States
JD Medical Group
Miami, Florida, United States
Miami Dermatology and Laser Research
Miami, Florida, United States
SouthCoast Research Center
Miami, Florida, United States
University of Miami
Miami, Florida, United States
Bio-Medical Research LLC
Miami, Florida, United States
South Miami Medical & Research Group
Miami, Florida, United States
New Horizon Research Center
Miami, Florida, United States
Skin Research of South Florida
Miami, Florida, United States
Well Pharma Medical Research, Corp.
Miami, Florida, United States
FXM Clinical Research - Miami
Miami, Florida, United States
Health and Life Research Institute
Miami, Florida, United States
University of Miami, Kendall Office
Miami, Florida, United States
Floridian Research Institute Llc
Miami, Florida, United States
Sanitas Research
Miami, Florida, United States
Wellness Clinical Research
Miami Lakes, Florida, United States
FXM Clinical Research - Miramar
Miramar, Florida, United States
GCP Research, Global Clinical professionals
St. Petersburg, Florida, United States
Advanced Clinical Research Institute
Tampa, Florida, United States
USF Health
Tampa, Florida, United States
Sidney P. Smith, MD, PC dba Georgia Skin & Cancer Clinic
Savannah, Georgia, United States
NorthShore University Health System
Skokie, Illinois, United States
Indiana University School of Medicine - Indiana CTSI Clinical Research Center
Indianapolis, Indiana, United States
Dawes Fretzin Clinical Research Group, LLC
Indianapolis, Indiana, United States
The South Bend Clinic, LLC
South Bend, Indiana, United States
Dermatology and Skin Cancer Specialists, LLC
Rockville, Maryland, United States
Oakland Hills Dermatology
Auburn Hills, Michigan, United States
CS Mott Center
Detroit, Michigan, United States
Wayne Health
Detroit, Michigan, United States
Henry Ford Medical Center - New Center One
Detroit, Michigan, United States
MediSearch Clinical Trials
Saint Joseph, Missouri, United States
Physician Research Collaboration, LLC
Lincoln, Nebraska, United States
University of New Mexico Health Sciences Center
Albuquerque, New Mexico, United States
OptiSkin Medical
New York, New York, United States
DermResearchCenter of New York, Inc.
Stony Brook, New York, United States
DJL Clinical Research, PLLC
Charlotte, North Carolina, United States
Darst Dermatology
Charlotte, North Carolina, United States
Bexley Dermatology Research
Bexley, Ohio, United States
Centricity Research Columbus Ohio Multispecialty
Columbus, Ohio, United States
Oregon Dermatology and Research Center
Portland, Oregon, United States
Dermatology Associates of Plymouth Meeting
Plymouth Meeting, Pennsylvania, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Columbia Dermatology & Aesthetics
Columbia, South Carolina, United States
Palmetto Clinical Trial Services - Greenville
Greenville, South Carolina, United States
Center for Clinical Studies
Houston, Texas, United States
Austin Institute for Clinical Research
Pflugerville, Texas, United States
Complete Dermatology
Sugar Land, Texas, United States
The Woodlands Dermatology Associates, PA
The Woodlands, Texas, United States
University of Utah
Murray, Utah, United States
Springville Dermatology - Springville/CCT Research
Springville, Utah, United States
The Education & Research Foundation, Inc.
Forest, Virginia, United States
Paratus Clinical Research Woden
Phillip, Australian Capital Territory, Australia
St George Dermatology & Skin Cancer Centre
Kogarah, New South Wales, Australia
Royal North Shore Hospital
St Leonards, New South Wales, Australia
Westmead Hospital
Westmead, New South Wales, Australia
Veracity Clinical Research
Woolloongabba, Queensland, Australia
North Eastern Health Specialists
Campbelltown, South Australia, Australia
The Queen Elizabeth Hospital
Woodville South, South Australia, Australia
Dr Rodney Sinclair Pty Ltd
East Melbourne, Victoria, Australia
The Alfred Hospital
Melbourne, Victoria, Australia
Institute for Skin, Health and Immunity
Mitcham, Victoria, Australia
The Royal Melbourne Hospital
Parkville, Victoria, Australia
Fremantle Dermatology
Fremantle, Western Australia, Australia
Université Libre de Bruxelles - Hôpital Erasme
Brussels, Bruxelles-capitale, Région de, Belgium
Cliniques universitaires Saint-Luc
Brussels, Bruxelles-capitale, Région de, Belgium
UZ Gent
Ghent, Oost-vlaanderen, Belgium
UZ Leuven
Leuven, Vlaams-brabant, Belgium
Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman
Liège, , Belgium
Diagnostic Consultative Center Aleksandrovska
Sofia, Sofia (stolitsa), Bulgaria
Diagnostic Consultative Centre (DCC) - Foкus 5
Sofia, Sofia (stolitsa), Bulgaria
Clinic EvroDerma
Sofia, Sofia (stolitsa), Bulgaria
MHAT Pazardzhik
Pazardzhik, , Bulgaria
Diagnostic Consultative Center 1 - Pernik
Pernik, , Bulgaria
Medical Center Exacta Medica
Pleven, , Bulgaria
Medical Center Prolet EOOD
Rousse, , Bulgaria
Diagnostic Consultative Center "Ascendent"
Sofia, , Bulgaria
Diagnostic - Consultative Center XXVIII - Sofia
Sofia, , Bulgaria
"Diagnostic - Consultative Center XX - Sofia" EOOD
Sofia, , Bulgaria
UMHAT "Prof. Dr. Stoyan Kirkovich"AD
Stara Zagora, , Bulgaria
Center for Skin and Venereal Diseases - Veliko Tarnovo
Veliko Tarnovo, , Bulgaria
Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD
Yambol, , Bulgaria
Dermatology Research Institute
Calgary, Alberta, Canada
Alberta Dermasurgery Centre
Edmonton, Alberta, Canada
The Skin Care Centre
Vancouver, British Columbia, Canada
Wiseman Dermatology Research Inc.
Winnipeg, Manitoba, Canada
SimcoDerm Medical and Surgical Dermatology Center
Barrie, Ontario, Canada
Medicor Research Inc
Greater Sudbury, Ontario, Canada
Sudbury Skin Clinique
Greater Sudbury, Ontario, Canada
DermEffects
London, Ontario, Canada
DermEdge Research
Mississauga, Ontario, Canada
The Centre for Clinical Trials
Oakville, Ontario, Canada
JRB Research Inc.
Ottawa, Ontario, Canada
York Dermatology Clinic & Research Centre
Richmond Hill, Ontario, Canada
North York Research Inc
Toronto, Ontario, Canada
Dermatology on Bloor - Research Toronto
Toronto, Ontario, Canada
Centre de Recherche Saint-Louis
Montreal, Quebec, Canada
Innovaderm Research Inc.
Montreal, Quebec, Canada
Centre de Recherche Saint-Louis
Sherbrooke, Quebec, Canada
Diex Recherche Sherbrooke
Sherbrooke, Quebec, Canada
Skinsense Medical Research
Saskatoon, Saskatchewan, Canada
Saskatoon Dermatology Centre
Saskatoon, Saskatchewan, Canada
Diex Recherche Quebec
Québec, , Canada
Centre de Recherche Dermatologique du Quebec metropolitain
Québec, , Canada
Alpha Recherche Clinique
Québec, , Canada
Beijing Friendship Hospital Affiliate of Capital University
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
The First Affiliated Hospital Of Fujian Medical University
Fuzhou, Fujian, China
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China
Guangzhou First People's Hospital
Guangzhou, Guangdong, China
The Affiliated Hospital of Guizhou Medical University
Guiyang, Guizhou, China
The First Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
NanYang First people's hospital
Nanyang, Henan, China
The First Hospital of Wuhan
Wuhan, Hubei, China
The Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The First Affiliated Hospital of Baotou Medical College
Baotou, Inner Mongolia, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
The First Hospital of Jilin University
Changchun, Jilin, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
Huashan Hospital, Fudan University
Shanghai, Shanghai Municipality, China
Chengdu second people's hospital
Chengdu, Sichuan, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
First Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Hangzhou Third Hospital
Hangzhou, Zhejiang, China
Sir Run Run Shaw Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Shanghai General Hospital
Shanghai, , China
Rosenpark Research GmbH
Darmstadt, Hesse, Germany
Klinikum Bielefeld gem. GmbH
Bielefeld, North Rhine-Westphalia, Germany
Klinikum Bielefeld Rosenhöhe
Bielefeld, North Rhine-Westphalia, Germany
Hautzentrum im Jahrhunderthaus
Bochum, North Rhine-Westphalia, Germany
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Hautarztpraxis Dr. Gerlach
Dresden, Saxony, Germany
Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
Dresden, Saxony, Germany
Universitätsklinikum Carl Gustav Carus Dresden
Dresden, Saxony, Germany
Hautarztpraxis Dr. Neubauer
Leipzig, Saxony, Germany
HNO-Praxis Dr. Kugler in Magdeburg
Magdeburg, Saxony-Anhalt, Germany
Magdeburger Company for Medical Studies and Services
Magdeburg, Saxony-Anhalt, Germany
Radiologie Ulrichshaus
Magdeburg, Saxony-Anhalt, Germany
Pécsi Tudományegyetem Klinikai Központ
Pécs, Baranya, Hungary
Synexus Magyarorszag Kft. (Gyula DRS)
Gyula, Bekes County, Hungary
Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
Szeged, Csongrád megye, Hungary
Óbudai Egészségügyi Centrum
Budapest, , Hungary
Orvostudomanyi Kutato es Fejleszto Kft
Debrecen, , Hungary
DERMA-B Egészségügyi és Szolgáltató
Debrecen, , Hungary
Debreceni Egyetem Klinikai Kozpont
Debrecen, , Hungary
Derm-Surg Kft.
Kaposvár, , Hungary
ASL1 Avezzano-Sulmona-L'Aquila
L’Aquila, Abruzzo, Italy
Presidio Ospedaliero Firenze Centro Piero Palagi
Florence, Firenze, Italy
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy
IRCCS Istituti Fisioterapici Ospitalieri
Roma, RM, Italy
Ospedale Israelitico
Rome, ROMA, Italy
Istituto Dermopatico Immacolata
Rome, ROMA, Italy
Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari
Cagliari, , Italy
Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari
Cagliari, , Italy
Japan Community Health Care Organization Chukyo Hospital
Nagoya, Aichi-ken, Japan
Toho University Sakura Medical Center
Sakura, Chiba, Japan
Juntendo University Urayasu Hospital
Urayasu, Chiba, Japan
Takarazuka City Hospital
Takarazuka, Hyōgo, Japan
Tokyo Medical University Ibaraki Medical Center
Inashiki-gun, Ibaraki, Japan
Kindai University Nara Hospital
Ikoma, Nara, Japan
Osaka Habikino Medical Center
Habikino, Osaka, Japan
Hamamatsu University Hospital
Hamamatsu, Shizuoka, Japan
Institute of Science Tokyo Hospital
Bunkyo-ku, Tokyo, Japan
Yamaguchi University Hospital
Ube, Yamaguchi, Japan
Trials in Medicine
Mexico City, Mexico City, Mexico
Clinica de Enfermedades Cronicas y Procedimientos Especiales, SC
Morelia, Michoacán, Mexico
Centro Regiomontano de Investigación
Monterrey, Nuevo León, Mexico
Servicios Hospitalarios de Mexico S.A. DE C.V.
Chihuahua City, , Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C.
Durango, , Mexico
Arké SMO S.A de C.V
Veracruz, , Mexico
Clinica Dermatoestetica Prywatny Gabinet Dermatologiczny I Alergologiczny Prof.Dr Hab.Med. Barbara Z
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka
Krakow, Lesser Poland Voivodeship, Poland
Krakowskie Centrum Medyczne
Krakow, Lesser Poland Voivodeship, Poland
ETG Warszawa
Warsaw, Masovian Voivodeship, Poland
Klinika Ambroziak Dermatologia
Warsaw, Masovian Voivodeship, Poland
Royalderm Agnieszka Nawrocka
Warsaw, Masovian Voivodeship, Poland
Specderm Poznanska sp.j.
Bialystok, Podlaskie Voivodeship, Poland
ClinicMed Daniluk, Nowak Spółka komandytowa
Bialystok, Podlaskie Voivodeship, Poland
Centrum Medyczne Angelius Provita
Katowice, Silesian Voivodeship, Poland
Twoja Przychodnia SCM
Szczecin, West Pomeranian Voivodeship, Poland
"DERMED" Centrum Medyczne Sp. z o.o.
Lodz, Łódź Voivodeship, Poland
Cardiovascular Radiology Institute
San Juan, , Puerto Rico
Clinical Research Puerto Rico
San Juan, , Puerto Rico
Centro de Audiología y Balance
San Juan, , Puerto Rico
Fakultna nemocnica s poliklinikou F.D.Roosevelta Banska Bystrica
Banská Bystrica, Banská Bystrica Region, Slovakia
SANARE, s.r.o
Svidník, Presov, Slovakia
Fakultna nemocnica Trnava
Trnava, Trnava Region, Slovakia
CLINIQ s.r.o.
Bratislava, , Slovakia
BeneDerma
Bratislava, , Slovakia
Derma therapy spol. s.r.o.
Bratislava, , Slovakia
Topskin pro s.r.o.
Košice, , Slovakia
Poliklinika ProCare Kosice s.r.o.
Košice, , Slovakia
AUDIKA
Córdoba, Andalusia, Spain
Hospital Universitario Reina Sofia
Córdoba, Andalusia, Spain
Hospital Germans Trias i Pujol
Badalona, Barcelona [barcelona], Spain
Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, Barcelona [barcelona], Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Catalunya [cataluña], Spain
Clínica Gaias - Santiago
Santiago de Compostela, Galicia [galicia], Spain
Hospital Universitario Infanta Leonor
Madrid, Madrid, Comunidad de, Spain
Clinica Universidad de Navarra
Madrid, , Spain
Hospital Universitario Infanta Leonor
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Clínica Gaias - Santiago
Santiago de Compostela, , Spain
Hospital Universitari i Politecnic La Fe
Valencia, , Spain
Hospital Universitario Miguel Servet
Zaragoza, , Spain
Chang Gung Memorial Hospital at Kaohsiung
Kaohsiung Niao Sung Dist, Kaohsiung, Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation-Linkou Branch
Taoyuan District, , Taiwan
Gazi University Health Research and Application Center Gazi Hospital
Ankara, , Turkey (Türkiye)
Bezmialem Vakf Üniversitesi
Istanbul, , Turkey (Türkiye)
West Middlesex University Hospital
Isleworth, England, United Kingdom
Guy's & St Thomas' NHS Foundation Trust
London, London, CITY of, United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-502518-98-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
B7981080
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.